Maslimomab

 ☒NcheckY (what is this?)  (verify)

Maslimomab is a mouse monoclonal antibody[1] and an immunosuppressive drug.[2] It is an anti-human T-cell receptor alpha/beta chain.[1]

References

  1. ^ a b "Proposed International Nonproprietary Names: Maslimomab" (PDF). WHO Drug Information. 5 (4). Geneva: World Health Organization: 201. 1991. Archived from the original (PDF) on 23 February 2012.
  2. ^ Pelletier JP, Mukhtar F (January 2020). "Passive monoclonal and polyclonal antibody therapies.". Immunologic Concepts in Transfusion Medicine. Philadelphia: Elsevier. pp. 251–348 (299). doi:10.1016/B978-0-323-67509-3.00016-0. ISBN 978-0-323-67510-9. PMC 7153350.
  • v
  • t
  • e
Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)
Antimetabolites
  • purine synthesis inhibitors
    • Azathioprine
    • Mycophenolic acid
  • dihydroorotate dehydrogenase inhibitors
    • Leflunomide
    • Teriflunomide
  • antifolate
    • Methotrexate
Macrolides/
other IL-2 inhibitors
IMiDs
Intracellular
(reception)
IL-1 receptor antagonists
mTOR
Extracellular
Antibodies
Monoclonal
Serum target
(noncellular)
Cellular
target
Unsorted
Polyclonal
-cept (Fusion)
Unsorted
  • v
  • t
  • e
Immune system
Human
Mouse
Chimeric
Humanized

Immune activation: Dostarlimab
Other: Ibalizumab

Chimeric + humanized
Interleukin
Human
Humanized
Veterinary
Inflammatory lesions
Mouse


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e